218 related articles for article (PubMed ID: 17651539)
1. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
3. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
Daniels SE; Desjardins PJ; Bird SR; Smugar SS; Tershakovec AM
Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
[TBL] [Abstract][Full Text] [Related]
5. Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies.
Michael Hill C; Sindet-Pederson S; Seymour RA; Hawkesford JE; Coulthard P; Lamey PJ; Gerry Cowan C; Wickens M; Jeppsson L; Dean AD; Svensson O
Clin Ther; 2006 Sep; 28(9):1279-95. PubMed ID: 17062301
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
Katz N; Ju WD; Krupa DA; Sperling RS; Bozalis Rodgers D; Gertz BJ; Gimbel J; Coleman S; Fisher C; Nabizadeh S; Borenstein D;
Spine (Phila Pa 1976); 2003 May; 28(9):851-8; discussion 859. PubMed ID: 12941996
[TBL] [Abstract][Full Text] [Related]
8. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
9. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies.
Schnitzer TJ; Weaver AL; Polis AB; Petruschke RA; Geba GP;
J Rheumatol; 2005 Jun; 32(6):1093-105. PubMed ID: 15940774
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.
Higuchi T; Iwama T; Yoshinaga K; Toyooka M; Taketo MM; Sugihara K
Clin Cancer Res; 2003 Oct; 9(13):4756-60. PubMed ID: 14581346
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain.
Desjardins PJ; Black PM; Daniels S; Bird SR; Fitzgerald BJ; Petruschke RA; Tershakovec A; Chang DJ
Curr Med Res Opin; 2004 Oct; 20(10):1523-37. PubMed ID: 15462686
[TBL] [Abstract][Full Text] [Related]
14. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
16. Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial.
Saper J; Dahlof C; So Y; Tfelt-Hansen P; Malbecq W; Loeys T; Barraclough E; Klipfel M; Lines C; Visser H; Reines S; Yuen E;
Headache; 2006 Feb; 46(2):264-75. PubMed ID: 16492236
[TBL] [Abstract][Full Text] [Related]
17. TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk.
Groom KM; Shennan AH; Jones BA; Seed P; Bennett PR
BJOG; 2005 Jun; 112(6):725-30. PubMed ID: 15924527
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain.
Chelly JE; Nissen CW; Rodgers AJ; Smugar SS; Tershakovec AM
Curr Med Res Opin; 2007 Jan; 23(1):195-206. PubMed ID: 17207303
[TBL] [Abstract][Full Text] [Related]
19. Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
Madigan D; Sigelman DW; Mayer JW; Furberg CD; Avorn J
Am Heart J; 2012 Aug; 164(2):186-93. PubMed ID: 22877803
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
